Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Covalon Technologies's enterprise value is $30.02 Mil.
Covalon Technologies's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $1.52 Mil. Therefore, Covalon Technologies's EV-to-EBITDA for today is 19.76.
The historical rank and industry rank for Covalon Technologies's EV-to-EBITDA or its related term are showing as below:
CVALF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -1779.96 Med: -6.53 Max: 415.35
Current: 19.76
During the past 13 years, the highest EV-to-EBITDA of Covalon Technologies was 415.35. The lowest was -1779.96. And the median was -6.53.
CVALF's EV-to-EBITDA is ranked worse than 67.25% of 513
companies
in the Medical Devices & Instruments industry
Industry Median: 14.17
vs CVALF: 19.76
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Covalon Technologies's PE Ratio (TTM) for today is calculated as:
Covalon Technologies's share price for today is $1.475.
Covalon Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.036.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Covalon Technologies's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Covalon Technologies's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Covalon Technologies EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Covalon Technologies's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Covalon Technologies's EV-to-EBITDA falls into.
Covalon Technologies's current Enterprise Value is $30.02 Mil.
Covalon Technologies's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.52 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Covalon Technologies (CVALF) has a EV-to-EBITDA of 19.76 as of Jul. 14, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Covalon Technologies. According to the industry distribution chart, Covalon Technologies ranks #345 out of 513 companies in the Medical Devices & Instruments industry, placing it in the top 67.3%.
Is Covalon Technologies' EV-to-EBITDA too high?
Covalon Technologies' current EV-to-EBITDA is 19.76. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.17. Covalon Technologies' value of 19.76 is 39.4% above this industry median. Based on the distribution chart, Covalon Technologies ranks #345 out of 513 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Covalon Technologies has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Covalon Technologies' EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Covalon Technologies ranks #345 out of 513 companies for EV-to-EBITDA. This places Covalon Technologies in the lower half of its industry. The industry median EV-to-EBITDA is 14.17. Covalon Technologies' value of 19.76 is 39.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.17, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Covalon Technologies's current EV-to-EBITDA of 19.76 is 39.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Covalon Technologies. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Covalon Technologies's current EV-to-EBITDA is 19.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Covalon Technologies stock overvalued right now?
Based on GuruFocus' analysis, Covalon Technologies (CVALF) is currently considered Fairly Valued. The stock's GF Value™ is $1.54, compared to a current price of $1.48 — trading 4.2% below its estimated fair value. The current EV-to-EBITDA is 19.76 and 39.4% above the Medical Devices & Instruments industry median of 14.17. Covalon Technologies' overall GF Score™ is 83/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Covalon Technologies (CVALF), the current EV-to-EBITDA is 19.76 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Covalon Technologies (CVALF) Overvalued in 2026?
Based on GuruFocus' analysis, Covalon Technologies stock appears to be undervalued.
The current stock price of $1.48 is trading 4.2% below its estimated GF Value™ of $1.54.
GuruFocus considers Covalon Technologies to be Fairly Valued.
Key valuation signals for CVALF:
EV-to-EBITDA: 19.76
GF Value™: $1.54 vs. price of $1.48 (4.2% below fair value)
Industry Position: 39.4% above the Medical Devices & Instruments median (#345 of 513)
No single metric tells the full story. See the CVALF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Covalon Technologies Ltd is engaged in the business of researching, developing, manufacturing, and marketing patent-protected medical products that improve patient outcomes in the areas of infection management, wound care, and surgical procedures. The company generates revenue through development contracts, licensing agreements, distribution contracts, and sales. Its products include IV dressings, surgical site protection products, vascular access protection products, and others, and its solutions include primary dressing cover, vascular access technologies, advanced wound care, sensitive skin solutions, custom medical coatings, and patient resource support.
83GF Score
Get the complete analysis for CVALF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CVALF has been successfully added to your 
